Biovica's CEO Anders Rylander summarizes the first quarter of the company's fiscal year 2017/18. The interview focuses on the latest recruitments that have been made during the quarter, the DiviTum technology, and regulatory approvals needed for the product in key markets. The interview ends with Anders Rylander commenting on the Biovica strategy until 2019. [...]
Uppsala, Sweden, May 22 2017. Samuel Rotstein has been appointed as Scientific Advisor to Biovica.
Uppsala 9 maj 2017. Biovica har erhållit nytt patent i Kina samt patentförlängning för bolagets tekniknologi i USA. Båda patenten avser Biovicas metod för att mäta tymidinkinas-aktivitet på en realtids-PCR-plattform. Det kinesiska patentet gäller till och 13:e maj 2031. Det amerikanska patentet har godkänts sedan tidigare men erhåller nu en förlängning med 430 dagar, [...]
Uppsala, Sweden May 9 2017. Biovica has received a new patent in China as well as patent extension for the company's technology in the United States. Both of the patents refer to Biovica's method of measuring thymidine kinase activity on a real-time PCR platform. The Chinese patent is valid until 13 May 2031. The U.S. patent [...]
Biovica will attend the ASCO (American Society of Clinical Oncology) Annual Meeting, an event that brings together 30 000 global oncology professionals. During ASCO Biovica will meet Pharma companies and oncologists to share the latest insights from the ongoing clinical trial programme and collaborations. Biovica has also been invited to present the latest DiviTum® data at [...]
Biovica CEO Anders Rylander is interviewed by the results presented at the AACR conference 1-5 April 2017. Read the interview here.
Biovicas vd Anders Rylander intervjuvas av Vator Securities med anledning av den just avslutade AACR-konferensen där Biovica deltog och presenterade nya resultat. Läs intervjun här.
The latest data of the DiviTum® assay as a unique efficacy marker of CDK4/6 inhibition is available on the American Association for Cancer Research (AACR) 2017 annual meeting website. Link to the results
Senaste data på DiviTum® som en unik effektmarkör för CDK4/6 hämmare finns nu tillgängligt på webbsidan för American Association for Cancer Research (AACR) årliga möte 2017. Länk till resultaten
Anders Rylander, CEO Biovica is interviewed in Analysguiden by Aktiespararna. The interview focus on the upcoming company IPO in march 2017. The interview is only available in Swedish.
Follow Biovica